Literature DB >> 19883228

In vivo assessment of dose volume and dose gradient effects on the tolerance dose of small liver volumes after single-fraction high-dose-rate 192Ir irradiation.

Christian Wybranski1, Max Seidensticker, Konrad Mohnike, Siegfried Kropf, Peter Wust, Jens Ricke, Lutz Lüdemann.   

Abstract

The aim of this study was to assess the dependence of the normal liver tissue threshold dose on the volume exposed and the catheter geometry-dependent dose gradients for single-fraction high-dose-rate brachytherapy of malignant liver lesions. A total of 50 patients with malignant liver tumors treated with CT-guided high-dose-rate 192Ir brachytherapy were included. Dose planning was performed using a three-dimensional CT data set acquired after percutaneous applicator positioning. Magnetic resonance imaging (MRI), performed 6 and 12 weeks after therapy, was analyzed retrospectively. All MRI data sets were merged with 3D dosimetry data. The border of hyperintensity on T2-weighted images (edema) and of hypointensity on T1-weighted images (impaired hepatocyte function) were analyzed to assess the radiation effect. The threshold isodose surface of the volume exposed was calculated from the 3D dosimetry data. The relationships between irradiated volume and threshold isodose surface as well as dose gradient and threshold isodose surface were evaluated over time. The median threshold dose of the volume exposed, characterized by hepatocyte dysfunction and edema, was approximately 13 Gy 6 weeks after irradiation and approximately 16 Gy at 12 weeks. We found a significant correlation between the normal liver tissue threshold dose and volume exposed (P < 0.0001). The 12-week threshold dose was estimated between approximately 14 Gy for 500 cm(3), approximately 16 Gy for 100 cm(3), and approximately 18 Gy for 10 cm(3) of irradiated volume. The results indicate that the dose gradient has no effect on the threshold liver dose. There was a significant shift of the threshold doses from regions of lower to regions of higher-dose exposure in the course of follow-up (P < 0.0001). Thus the normal liver tissue threshold dose is dependent on the volume exposed but not on the dose gradient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19883228     DOI: 10.1667/RR1773.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  5 in total

1.  Radiobiological restrictions and tolerance doses of repeated single-fraction hdr-irradiation of intersecting small liver volumes for recurrent hepatic metastases.

Authors:  Ricarda Rühl; Lutz Lüdemann; Anna Czarnecka; Florian Streitparth; Max Seidensticker; Konrad Mohnike; Maciej Pech; Peter Wust; Jens Ricke
Journal:  Radiat Oncol       Date:  2010-05-27       Impact factor: 3.481

2.  Safety margin in irradiation of colorectal liver metastases: assessment of the control dose of micrometastases.

Authors:  Max Seidensticker; Peter Wust; Ricarda Rühl; Konrad Mohnike; Maciej Pech; Gero Wieners; Günther Gademann; Jens Ricke
Journal:  Radiat Oncol       Date:  2010-03-24       Impact factor: 3.481

3.  In vivo assessment of catheter positioning accuracy and prolonged irradiation time on liver tolerance dose after single-fraction 192Ir high-dose-rate brachytherapy.

Authors:  Lutz Lüdemann; Christian Wybranski; Max Seidensticker; Konrad Mohnike; Siegfried Kropf; Peter Wust; Jens Ricke
Journal:  Radiat Oncol       Date:  2011-09-05       Impact factor: 3.481

4.  Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity.

Authors:  Max Seidensticker; Ricarda Seidensticker; Robert Damm; Konrad Mohnike; Maciej Pech; Bruno Sangro; Peter Hass; Peter Wust; Siegfried Kropf; Günther Gademann; Jens Ricke
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

5.  Nonrigid 3D medical image registration and fusion based on deformable models.

Authors:  Peng Liu; Benjamin Eberhardt; Christian Wybranski; Jens Ricke; Lutz Lüdemann
Journal:  Comput Math Methods Med       Date:  2013-04-18       Impact factor: 2.238

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.